Skip to main content

Advertisement

Table 4 Medication Trials in Hepatitis B and Hepatitis C Coinfected Patients

From: Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection

Author [Ref] Patients # Treatment × Duration HCV SVR HBV DNA negative HBsAg loss HBeAg loss SBR
Interferon Trials
Gehenot [53] Anti-HCV+ HCV RNA+ HBsAg+ HBV DNA- 16 IFNα 3 MU TIW × 6 mo N/A N/A 12.5% N/A 19%
Weltman [3] Anti-HCV+ HBsAg+ 8 IFNα 3 MU TIW × 6 mo N/A N/A 12.5% N/A 12.5%
Guptan [54] Anti-HCV+ HCV RNA+ HBsAg+ HBV DNA+ 7 IFNα 6 MU TIW × 6 mo 29% 86% 28.6% 100% 0%
Villa [55] Anti-HCV+ HCV RNA+ HBsAg+ 30 IFNα 9 MU TIW × 6 mo or 6 MU TIW × 6 mo 16.7% (31%)* 66.7% (100%)* 3% N/A 20% (37.5%)*
Utili [23] Anti-HCV+ HBeAg ± HCV RNA ± 16 IFNα 5 MU TIW × 12 mo 43.8% N/A N/A 15.4% 50%
Zignego [10] Anti-HCV+ HBV DNA+ HBsAg- 14 IFNα 3 MU TIW × 12 mo 0% 0% N/A N/A 0%
Liaw [56] Anti-HCV+ HBV DNA+ HBeAg+ 15 IFNα 9 MU TIW × 14 wk or 4–6 MU TIW × 12 wk 0% 6.7% 6.7% 6.7% 6.7%
Interferon plus ribavirin trials
Liu [57] Anti-HCV+ HCV RNA+ HBsAg+ 21 IFNα 6 MU TIW × 3 mo + 3 MU TIW × 3 mo + ribavirin × 6 mo 43% 35% 0% 100% 43%
Hung [58] Anti-HCV+ HCV RNA+ HBsAg+ 36 IFNα 3–5 MU TIW + ribavirin × 6 mo 69% 11% 0% 0% 56%
Chuang [59] Anti-HCV+ HCV RNA+ HBsAg+ 42 IFNα 6 MU TIW + ribavirin × 6 mo 69% 31.3% 14.3% 50% 54.8%
Interferon plus lamivudine trials
Marrone [61] HBeAg+ HBV DNA+ HCV RNA+ 8 IFN 5 MU TIW × 12 mo + lamivudine × 18 mo 50% 37.5% 0% 37.5% 50%
  1. *9 MU arm. Abbreviations: # = number of patients; Ref = reference; SVR = sustained virologic response; SBR = sustained biochemical response; HCV = hepatitis C virus; HBV = hepatitis B virus; Anti-HCV = Antibody to hepatitis C virus; HBsAg = hepatitis B surface antigen; HBeAg = hepatitis B e antigen; mo = month; wk = week; TIW = thrice weekly; IFNα = interferon alfa